TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›GLSI›Financials
Annual statements · SEC XBRL · FY2019 – FY2025

Greenwich LifeSciences, Inc. (GLSI) financials

Income statement

Greenwich LifeSciences, Inc. (GLSI) income statement, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$3.43M-$1.86M-$4.60M-$8.04M-$9.33M-$17.6M-$19.4M
Net income-$3.43M-$1.86M-$4.57M-$7.83M-$8.89M-$17.4M-$19.4M
EPS (diluted)-$1.52-$0.20-$0.35-$0.61-$0.69-$1.34-$1.43

Cash flow

Greenwich LifeSciences, Inc. (GLSI) cash flow, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$293K-$1.15M-$4.29M-$6.20M-$6.48M-$7.27M-$9.91M
Share buybacks———$7.54M———

Balance sheet

Greenwich LifeSciences, Inc. (GLSI) balance sheet, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$6.83K$28.7M$27.2M$13.5M$6.99M$4.09M$6.18M
Total assets$26.7K$28.7M$27.2M$13.5M$6.99M$4.09M$6.18M
Total liabilities$1.38M$1.05M$385K$263K$294K$3.19M$2.55M
Shareholders' equity-$1.35M$27.6M$26.8M$13.2M$6.70M$909K$353K
Retained earnings-$27.2M-$29.1M-$33.6M-$41.5M-$50.4M-$67.8M-$87.1M
Shares (wtd avg diluted)8.46M12.7M13.1M12.9M12.8M13.0M13.5M

Every figure is extracted from Greenwich LifeSciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does GLSI pay a dividend?
Greenwich LifeSciences, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full GLSI analysis — verdict, score & filings →Is GLSI a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.